The financials
CG Oncology, Inc. by the numbers
CG Oncology, Inc. (CGON) reported revenue of $1.2M in Q2 2026 (quarter ended June 30, 2026). That came with net loss of $79M. For the full year FY2025, revenue was $4.0M (+255% year on year) and net income −$161M. Its largest product in 2026-Q1 was Commercial And Development at $1.1M, 99% of the disclosed total, just ahead of License And Collaboration at 1.3%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.2M | $0 | n/a |
| Operating income | −$86M | −$49M | n/a |
| Net income | −$79M | −$41M | n/a |
| Diluted EPS | −$0.90 | −$0.54 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Commercial And Development | $1.1M | 99% |
| License And Collaboration | $14K | 1.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $1.1M (-35%)
Segment Latestquarter on quarteryear on year
- Commercial And Development$1.1M$1.1MQoQ -29%year on year --29%-
- License And Collaboration$14.0K$14.0KQoQ -91%year on year -73%-91%-73%